Trial Profile
A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)-Associated Osteomalacia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Burosumab (Primary)
- Indications Nevus; Osteomalacia
- Focus Registrational; Therapeutic Use
- Sponsors Kyowa Kirin; Ultragenyx Pharmaceutical
- 15 Nov 2023 Results assessing Healthcare Resource Utilization from histories of adults with TIO not curable by surgery presented at the ACR Convergence 2023
- 01 Nov 2023 Results of exploratory analysis assessing mixed methods analysis of change from baseline after 144 weeks of burosumab treatment alongside qualitative data from exit interviews with 8 of 14 trial participants to evaluate meaningful treatment effects from a patient perspective published in the Journal of Bone and Mineral Research
- 27 Jan 2021 Status changed from active, no longer recruiting to completed.